https://www.selleckchem.com/products/c75.html
23), 14.9 months (4.72-25.08) for Group B, and was not reached in GroupA (p=0.001). The estimated median overall survival in Group C was 35 months (26.69-43.31), and was not reached in Groups A and B (p=0.001). The pathological response ratio to systemic therapy correlates with survival in patients undergoing CRS/HIPEC. This study supports the utilization of preoperative therapy for better patient selection, with a potential impact on survival. The pathological response ratio to systemic therapy correlates with survival in patients undergoi
Like
Comment
Share
